tradingkey.logo

Humacyte Inc <HUMA.OQ> expected to post a loss of 19 cents a share - Earnings Preview

ReutersMay 6, 2025 1:21 PM
  • Humacyte Inc HUMA.OQ HUMA.O is expected to show a rise in quarterly revenue when it reports results on May 8 (estimated) for the period ending March 31 2025

  • The Durham North Carolina-based company is expected to report revenue of $760.33 thousand, according to the mean estimate from 6 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Humacyte Inc is for a loss of 19 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 0.6% in the last three months. ​

  • Wall Street's median 12-month price target for Humacyte Inc is $8.00​, above​ its last closing price of $1.26. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.27

-0.25

-0.16

Beat

36

Sep. 30 2024

-0.25

-0.25

-0.33

Missed

-32.8

Jun. 30 2024

-0.24

-0.24

-0.48

Missed

-101.7​

Mar. 31 2024

-0.22

-0.22

-0.29

Missed

-28.9

​​Dec. 31 2023

-0.25

-0.24

-0.24

Met

2

Sep. 30 2023

-0.25

-0.25

-0.25

Met

1.3​

Jun. 30 2023

-0.22

-0.22

-0.22

Met

-0.1

Mar. 31 2023

-0.21

-0.21

-0.36

Missed

-71.8

This summary was machine generated May 6 at 13:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI